Boule Diagnostics presented a new generation of automated blood cell counters at the leading trade fair Medica in Düsseldorf. The instruments will gradually replace current products under the brands Medonic and Swelab.
It is the first time since 2006 that Boule launches new instruments in the important 3-part market for blood cell counting. The reception was very positive from Boule’s resellers at the trade fair. Developing new instruments is part of the fortifying of Boule’s position on the world market for smaller blood cell counters.
“With the new instruments, we have introduced a number of improvements to meet the ever increasing demands on communication between instruments and customer information systems. We have also improved user interface and the systems’ performance. We believe that we will gain additional competitiveness with the new systems”, says Ernst Westman, President and CEO, Boule Diagnostics AB.
The instruments will be delivered from the second quarter of 2015.
For more information, please contact:
Ernst Westman, President and CEO, Boule Diagnostics AB, phone +46 708-60 88 63
The information in this press release is such that Boule Diagnostics AB must disclose it in accordance with the Securities Market Act and/or the Financial Instruments Trading. The information was submitted for publication in Swedish at 8:30 am (CET), November 17, 2014.
TO THE EDITORS
About Boule Diagnostics AB
Boule Diagnostics AB is a fast-growing diagnostics company, developing and manufacturing systems and consumables for hematology diagnostics for the public healthcare providers worldwide. The company is primarily focused on small and medium-sized hospitals, clinics and laboratories in outpatient care as well as other diagnostics companies in both human and veterinary hematology. The group is comprised of operating subsidiaries in Sweden, the US and China. The Boule Diagnostics share is traded on NASDAQ OMX Nordic since 2011. http://www.boule.se
Release